US Prostate Laser Surgery Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

US Prostate Laser Surgery Market Trends and Insights

Aging US BPH Burden and Rising Surgical Complexity

The aging male population in the United States, particularly those with BPH and LUTS, is driving the prostate laser surgery market. BPH prevalence among men aged 65 and older ranged from 29% to 35% annually in Medicare populations, with 600,000 new cases identified each year. This group, burdened with comorbidities like hypertension (81%), coronary artery disease (39%), and diabetes (35%), increasingly prefers procedures offering better hemostasis and simpler perioperative management.^{[2]American Urological Association, “Benign Prostatic Hyperplasia (BPH) Guideline,” AUA Quality and Guidelines, auanet.org} Despite this, only 2% of BPH surgeries involved enucleation from 2014 to 2023, indicating significant growth potential as referrals shift to high-volume laser centers equipped for complex cases.

Guideline-Backed Shift Toward Size-Independent Laser Procedures

The United States prostate laser surgery market gained momentum when the AUA recommended HoLEP and ThuLEP as size-independent solutions for LUTS and BPH, alongside GreenLight PVP for patients at higher bleeding risk. This guidance removed the perception that enucleation is only for large glands. Academic centers have already seen laser enucleation rise from 13.7% of BPH surgeries 27.7% in early 2024, with annual utilization increasing by 52%. Community practices are also aligning with these guidelines, ensuring evidence-based case selection over outdated practices.

Outpatient Migration and Bleeding-Risk Advantages

The United States prostate laser surgery market is benefiting from the shift to outpatient care. Most prostate laser procedures are now performed in outpatient settings, supported by Medicare reimbursement favoring ASCs over hospital outpatient departments. A 2025 review showed 91% of HoLEP patients achieved same-day discharge with fewer complications than inpatient cases. Laser procedures for anticoagulated patients reduce scheduling and recovery challenges, enabling streamlined same-day care.^{[3]James W. Greenberg et al., “Contemporary Trends of Benign Prostatic Hyperplasia Procedures in the AUA Quality Registry, Are We Moving the Needle Toward More Minimally Invasive Treatments?,” AUA Journals, auajournals.org} This trend is driving demand for disposable fibers and accessories, as ASCs prefer single-use workflows.

Wait-List Pressure for Catheter-Dependent BPH Patients

The United States prostate laser surgery market faces a backlog of patients awaiting care. A study on 91 BPH patients in urinary retention awaiting HoLEP reported a median wait time of 220 days, with complications in 56% of cases, including urinary tract infections (63%), hematuria (47%), and urosepsis (16%). The median care cost per patient was USD 5,315.95, highlighting clinical and financial burdens. Patients delayed over six months from catheterization to surgery had a 2.11 times higher treatment failure risk compared to catheter-naive peers. Addressing this backlog requires more trained surgeons and operating room access to convert delayed cases into procedures.

HoLEP and ThuLEP Training Bottleneck

The United States prostate laser surgery market faces a significant challenge in surgeon training. As of 2024, only 12% of endourology fellowships in the country included formal HoLEP training, and 25% of surveyed HoLEP surgeons reported not teaching the technique. Achieving proficiency in HoLEP and ThuLEP typically requires 40 to 60 supervised cases, a hurdle for community hospitals with limited procedure volumes. This has created a divide where academic and regional centers advance enucleation expertise, while community practices focus on PVP or non-laser MIST. Without scalable training pathways, growth in the United States prostate laser surgery market will remain uneven across regions and facility types.

Non-Laser BPH Alternatives Divert Capital and Case Volume

The United States prostate laser surgery market competes with non-laser BPH therapies that require lower capital investment and simpler office setups. Established options like UroLift, Rezūm, and aquablation have strong clinical evidence and reimbursement frameworks, diverting demand from laser surgeries. In June 2025, Boston Scientific's Rezūm system received FDA clearance to treat prostates up to 150 cm³, encroaching on a segment traditionally served by laser procedures. PROCEPT BioRobotics has also strengthened aquablation's position for larger prostates, with studies showing comparable efficacy to laser enucleation and reduced ejaculatory dysfunction. 

Segment Analysis

By Offering: Consumables Economics Underpin Recurring Revenue Dominance

In 2025, Laser Fibers and Disposable Consumables contributed 46.21% of the revenue, making them the largest offering in the United States prostate laser surgery market. This reflects the recurring revenue model, as each HoLEP or ThuFLEP procedure requires single-use fibers and related items. With case volumes expected to rise from 2026 to 2031, this category will remain a reliable revenue stream, scaling directly with procedure counts.

Capital Laser Systems held a smaller share but are critical for driving future disposable demand. Each new platform placed in an ASC or community hospital secures long-term accessory and fiber usage. Morcellators and Accessory Instruments, growing at 8.12% CAGR through 2031, are driven by the increasing adoption of enucleation procedures, where morcellation is essential post-adenoma separation.

By Procedure Type: Enucleation's Evidence Base Challenges PVP's Procedural Primacy

Photoselective Vaporization of the Prostate (PVP) accounted for 40.45% of procedure-type revenue in 2025, maintaining its lead in the United States prostate laser surgery market. Its dominance stems from widespread adoption, familiarity with the GreenLight platform, and suitability for lower-complexity cases in outpatient settings. However, enucleation procedures are steadily gaining traction, reshaping the procedural mix.

Laser enucleation increased from 13.7% of BPH surgical procedures in 2018 to 24.4% in 2021-2022 across academic centers. Thulium Fiber Laser Enucleation of the Prostate, growing at 7.12% CAGR through 2031, is supported by FDA clearances and clinical evidence. This shift creates a balanced procedure mix, with PVP retaining its broad base and enucleation expanding in complex cases.

By Laser Technology: Thulium Fiber Laser Accelerates While Green Laser Defends Its Base

The 532 nm KTP and Green Laser segment held 38.30% of technology revenue in 2025, leading the United States prostate laser surgery market. Its position is supported by a large installed base, clinical history, and alignment with bleeding-risk indications. However, its narrower procedural range compared to thulium platforms limits its versatility.

Thulium fiber laser, growing at 9.10% CAGR through 2031, is gaining traction due to its procedural flexibility and recent FDA-cleared systems. Holmium:YAG systems remain relevant due to surgeon familiarity and their role in enucleation-heavy programs, creating a competitive landscape as providers weigh mature platforms against newer options.

By Site of Care: Ambulatory Surge Redefines Capital and Consumable Demand Geography

Hospital Outpatient Departments (HOPDs) accounted for 54.66% of site-of-care revenue in 2025, maintaining their lead in the United States prostate laser surgery market. Their dominance is attributed to high-powered lasers, anesthesia support, and trained teams, making them the preferred setting for complex cases. However, alternative care models are emerging.

Ambulatory Surgery Centers (ASCs), growing at 9.05% CAGR through 2031, are gaining traction due to compact platforms and same-day discharge protocols. A systematic review in 2025 reported 91% same-day discharge for HoLEP patients, driving faster growth in ambulatory settings compared to hospitals. Disposable fibers benefit from ASCs' preference for streamlined workflows.

By Prostate Size Treated: Very-Large-Gland Volume Reshapes the Procedure Mix

In 2025, the 30 g to 80 g prostate-size band accounted for 38.99% of revenue, making it the largest treated-size segment in the United States prostate laser surgery market. This range covers most BPH referrals and is served by multiple technologies, though it faces competition from non-laser MIST therapies.

The more-than-150 g cohort is projected to grow at 8.77% CAGR through 2031, driven by laser enucleation's ability to manage very large glands endoscopically. Evidence supports ThuFLEP's non-inferiority to HoLEP for large-gland enucleation, while aquablation adds competitive pressure with comparable efficacy and reduced ejaculatory dysfunction in large prostates.

Geography Analysis

In 2025, Hospital Outpatient Departments accounted for 54.66% of the United States prostate laser surgery market share. This reflects a trend where large urban and suburban health systems dominate procedural volumes. The Southeast and Midwest states experience the highest surgical demand due to aging male populations and a significant chronic disease burden. Additionally, academic and tertiary-care referral centers in the Northeast and West Coast lead the market, driven by early adoption of enucleation training and advanced case management practices.

Ambulatory Surgery Centers (ASCs) are projected to grow at a 9.05% CAGR through 2031, strengthening the United States prostate laser surgery market in Sun Belt states like Texas, Florida, and Arizona. These regions attract investments due to their aging populations, high procedural demand, and readiness to adopt compact laser platforms. This shift moves growth opportunities from traditional hospital campuses to cost-efficient outpatient networks, increasing the importance of vendors capable of supporting deployment, training, and disposables across dispersed ASC networks.

Community hospitals and rural areas face significant training challenges, limiting their ability to meet surgical demand. Catheter-dependent BPH patients in these regions experience acute wait-list pressures, leading to complications from delayed treatment and higher failure rates after prolonged catheterization. Consequently, the growth of the United States prostate laser surgery market is influenced as much by provider capacity as by patient demand.